Advertisement

Novel fluoroimmunoassay for ovarian cancer biomarker CA-125

  • Davin Sok
  • Lisa-Jo A. Clarizia
  • Leslie R. Farris
  • Melisenda J. McDonald
Short Communication

Abstract

Cancer antigen 125 (CA-125) is a glycoprotein biomarker that denotes the presence of ovarian and reproductive cancers in women, with serum concentrations of CA-125 greater than 35 U/ml considered indicative of potential malignancies. A fluorescent immunoassay recently developed in our laboratory employing the ALYGNSA antibody-orientation system has been used to measure CA-125 levels. This system displayed significantly increased sensitivity with a detection limit of 1.5 U/ml compared to that of a commercial CA-125 enzyme-linked immunosorbent assay (15 U/ml) This tenfold lower level of detection of the ALYGNSA CA-125 assay should permit better identification and monitoring of ovarian cancer.

Keywords

Fluoroimmunoassay ELISA Cancer biomarker CA-125 

Notes

Acknowledgments

This work was supported by NSF grant # EEC-0425826 and a University of Massachusetts System-Wide CVIP award (MJM). One of us (DS) participated in the NSF Research Experience for Undergraduates (REU). Special thanks to Sinang Chourb and Brian Mackness for their useful discussions.

References

  1. 1.
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smiga C, Thun MJ (2006) CA Cancer J 56:106–130CrossRefGoogle Scholar
  2. 2.
    Markman M, Webster K, Zanotti K, Peterson G, Kulp B, Belinson J (2004) Gynecol Oncol 93:715–717CrossRefGoogle Scholar
  3. 3.
    American Cancer Society (2007) Atlanta: American Cancer SocietyGoogle Scholar
  4. 4.
    Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, Podratz KC, Maihle NJ (2005) Cancer Epidemiol Biomark Prev 14:306–318CrossRefGoogle Scholar
  5. 5.
    Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen T-H, Wiggins WS, Mapes JP, Mansfield BP (2008) Cancer Epidemiol Biomark Prev 17:2872–2881CrossRefGoogle Scholar
  6. 6.
    Lowe K, Shah C, Wallace E, Anderson G, Paley P, McIntosh M, Andersen M, Scholler N, Bergan L, Thorpe J, Urban N, Drescher C (2008) Cancer Epidemiol Biomark Prev 17:2480–2487CrossRefGoogle Scholar
  7. 7.
    Hermsen B, Mensdorff-Pouilly S, Berkhof J, van Diest P, Gille J, Menko F, Blankenstein M, Kenemans P, Verheijen R (2007) J Clin Oncol 25:1383–1389CrossRefGoogle Scholar
  8. 8.
    Clarizia LJA (2006) Ph.D. Thesis University of Massachusetts, Lowell MassachusettsGoogle Scholar
  9. 9.
    Clarizia LJA, Sok D, Wei M, Mead J, Barry C, McDonald MJ (2009) Anal Bioanal Chemistry (in press)Google Scholar
  10. 10.
    Jacobs IJ, Menon U (2004) Molecular & Cellular Proteomics 34:355–366CrossRefGoogle Scholar
  11. 11.
    Crowther JR (1995) The ELISA guidebook. Humana, New Jersey USA, pp 9–44CrossRefGoogle Scholar
  12. 12.
    Visintin I, Feng Z, Longton G, Ward D, Alvero A, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz P, Mor G (2008) Clin Cancer Res 14:1065–1072CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Davin Sok
    • 1
  • Lisa-Jo A. Clarizia
    • 1
  • Leslie R. Farris
    • 1
  • Melisenda J. McDonald
    • 1
  1. 1.Biochemistry Program, Department of Chemistry, College of Arts and SciencesUniversity of MassachusettsLowellUSA

Personalised recommendations